Respiratory Disease and Cystic Fibrosis
Sciclone Pharmaceuticals International (SG) Pte. Ltd. is involved in clinical research focused on cystic fibrosis, with interest in the management of chronic respiratory disease and its inflammatory burden in adult patients.
- Cystic Fibrosis
- Adult Respiratory Care
- Pulmonary Disease
The sponsor’s research activity in this area reflects attention to conditions affecting airway function and long-term lung health.
Inflammation and Immune Modulation
The sponsor’s clinical interest extends to inflammatory processes linked to cystic fibrosis, including work centered on cytokine activity in the respiratory tract.
- Cytokine Signaling
- Inflammatory Biomarkers
- Immune Response
Relevant markers include IL-1β, IL-8, IL-17A, IL-6, and TNF-alpha, highlighting a therapeutic focus on immune activity in sputum.
Therapeutic Development in Rare Disease
Its research portfolio includes investigation of Thymosin alpha 1 in the setting of cystic fibrosis, indicating interest in therapies for a chronic rare disease population.
- Thymosin alpha 1
- Rare Disease Therapy
- Chronic Disease Management
This area aligns with clinical evaluation of treatment options aimed at respiratory and immune-related disease features.
